Annual report pursuant to Section 13 and 15(d)

Goodwill and Intangible Assets

v3.24.1
Goodwill and Intangible Assets
12 Months Ended
Dec. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]  
Goodwill and Intangible Assets GOODWILL AND INTANGIBLE ASSETS

Goodwill

The following table summarizes the changes in the carrying amounts of goodwill (in thousands):

 

 

Carrying
Amount

 

Balance - December 31, 2022:

 

$

 

Acquisition of Cultured Foods

 

 

334

 

Translation adjustment

 

 

8

 

Balance - December 31, 2023:

 

$

342

 

As of December 31, 2023, the Company performed its annual goodwill impairment analysis following the steps laid out in ASC 350-20-35-3C. The Company's annual impairment analysis included a qualitative assessment to determine if it was necessary to perform the quantitative impairment test. After performing a qualitative test the Company concluded that it was more likely than not that the fair value of the Company exceeds its carrying value of goodwill. Accordingly, there was no indication of impairment and the qualitative impairment test was not performed. The Company did not record any goodwill impairment charges for the year ended December 31, 2023. The Company did not have any goodwill as of December 31, 2022.

Intangible Assets

The following table summarizes the intangible assets and the related accumulated amortization (in thousands):

 

 

December 31,
2023

 

 

December 31,
2022

 

Gross carrying amount

 

$

79

 

 

$

251

 

Accumulated amortization

 

 

(1

)

 

 

-

 

Net carrying amount

 

$

78

 

 

$

251

 

The Company evaluated, on the basis of the weight of the evidence, the significance of all identified events and circumstances that could affect the significant inputs used to determine the fair value of the IPR&D for determining whether it is more likely than not that the IPR&D asset is impaired. After assessing the totality of events and circumstances and their potential effect on significant inputs to the fair value determination, the Company determined that it is more likely than not that the IPR&D asset is impaired. As such, the Company has estimated the fair value of the IPR&D and performed the quantitative impairment test. Based on the quantitative impairment test, the Company determined that its IPR&D is impaired by $0.3 million. As a result, the Company recorded this impairment to reduce its intangible assets on its consolidated balance sheet as of December 31, 2023 and recorded the corresponding impairment expense, which is included in selling, general and administrative expense in the Company's consolidated statements of operations for the year ended December 31, 2023. The Company also recorded an impairment charge to reduce its intangible assets of $1.2 million during the year ended December 31, 2022.

Changes in the carrying amounts of intangible assets are summarized below (in thousands):

 

In-process research and development

 

 

Trade names

 

 

Customer relationships

 

 

Total

 

Balance - December 31, 2021:

 

$

1,485

 

 

$

 

 

$

 

 

$

1,485

 

Impairment

 

 

(1,234

)

 

 

 

 

 

 

 

 

(1,234

)

Balance - December 31, 2022:

 

 

251

 

 

 

 

 

 

 

 

 

251

 

Impairment

 

 

(251

)

 

 

 

 

 

 

 

 

(251

)

Acquisition of Cultured Foods

 

 

 

 

 

52

 

 

 

26

 

 

 

78

 

Amortization

 

 

 

 

 

(1

)

 

 

 

 

 

(1

)

Translation adjustments

 

 

 

 

 

1

 

 

 

 

 

 

1

 

Balance - December 31, 2023:

 

$

 

 

$

52

 

 

$

26

 

 

$

78

 

The Company did not incur costs to renew or extend the term of acquired intangible assets for the years ended December 31, 2023 and 2022. The estimated amortization expense for the Company's intangible assets is not significant in any future individual fiscal year.